Hims may have an chance to grow peptides business as a potential revenue driver, with FDA review in 2026 shaping the opportunity.
Source: US Top News and Analysis
Related Posts
Cleveland Fed President Hammack expects interest rates to stay on hold ‘for a good while’
The central bank official advocated a patient approach as officials watch incoming data for clues…
SpaceX lines up 21 banks for mega IPO, code-named project Apex
SpaceX is working with at least 21 banks on its initial public offering, in one…
Trump to attend Supreme Court arguments on birthright citizenship executive order
Trump’s executive order says babies born in the U.S. are not entitled to citizenship if…